Compare GLNG & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLNG | PTCT |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.7B |
| IPO Year | 2002 | 2006 |
| Metric | GLNG | PTCT |
|---|---|---|
| Price | $49.72 | $81.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 17 |
| Target Price | $50.63 | ★ $80.65 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 11-21-2023 | 05-07-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | $3.14 | N/A |
| Revenue Next Year | $8.66 | $17.70 |
| P/E Ratio | $80.48 | ★ N/A |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $35.02 | $43.18 |
| 52 Week High | $57.79 | $87.50 |
| Indicator | GLNG | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 62.46 |
| Support Level | $48.48 | $73.41 |
| Resistance Level | $51.92 | $87.50 |
| Average True Range (ATR) | 1.23 | 3.11 |
| MACD | 0.04 | 0.31 |
| Stochastic Oscillator | 33.83 | 65.33 |
Golar LNG Ltd designs, converts, owns, and operates marine infrastructure for the liquefaction of natural gas and provides floating liquefied natural gas (FLNG) services. It offers solutions for gas resource holders to develop and utilize gas reserves, including stranded, associated, flared, or underutilized resources. The company's reportable segments are: i) FLNG: includes the operations of FLNG vessels and projects, and ii) Corporate and other: includes legacy shipping segment activities, vessel management, floating storage and regasification unit services for third parties. The majority of the company's revenue is derived from the FLNG segment. Geographically, it generates the maximum revenue from Cameroon.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.